I’m a LT holder…..
D. Boral Capital says the selloff in shares of Humacyte (HUMA) following the company’s $50M capital raise is a buying opportunity. While the stock weakness reflects dilution concerns, the additional capital significantly strengthens Humacyte’s financial position, the analyst tells investors in a research note. With its FDA-approved cellular tissue-engineered vessels “poised to revolutionize vascular trauma,” D. Boral views the current pullback as an opportunity to accumulate shares. It keeps a Buy rating on Humacyte with a $25

D. Boral Capital says the selloff in shares of Humacyte (HUMA) following the company’s $50M capital raise is a buying opportunity. While the stock weakness reflects dilution concerns, the additional capital significantly strengthens Humacyte’s financial position, the analyst tells investors in a research note. With its FDA-approved cellular tissue-engineered vessels “poised to revolutionize vascular trauma,” D. Boral views the current pullback as an opportunity to accumulate shares. It keeps a Buy rating on Humacyte with a $25

Shortly after FDA approval, Humacyte began receiving requests for quotations for Symvess from hospitals. Twenty-one hospitals have already initiated the VAC approval process, with additional hospitals expected to commence the process. These hospitals are a mix of leading trauma centers that were participants in Humacyte clinical studies combined with institutions newly introduced to Symvess.

Study news out! Positive results

Looking for return of triple digits this week.

Craziest thing ever…..?

Gotcha…

Are you in too TT? Shhh….

Happy Saturday Monk! Would you be long a thus point? .55?

Is there a strategy currently in place to get our government, current administration, fully aware of what I used has to offer the completely made in America will resonate strong with Trump and Vance

Good morning TT. Are you holding a position or trading shares?

Technical chart is positive.

Technically, it’s movement slants negative. Need another short squeeze.

Posted 15 mins ago….On February 27, 2025, NLS Pharmaceutics announced new preclinical data for AEX-2, a non-sulfonamide dual orexin receptor agonist, highlighting its potential for treating narcolepsy and related neurological disorders. The findings suggest AEX-2 offers a safer and more targeted alternative to existing therapies, with significant advancements in wakefulness enhancement, REM sleep preservation, and cataplexy reduction. The company, in collaboration with Aexon Labs, is also exploring the broader therapeutic applications of AEX-2 and AEX-41 in neurodegenerative and metabolic disorders, with plans to advance these compounds into clinical trials by 2026.

On February 27, 2025, NLS Pharmaceutics announced new preclinical data for AEX-2, a non-sulfonamide dual orexin receptor agonist, highlighting its potential for treating narcolepsy and related neurological disorders. The findings suggest AEX-2 offers a safer and more targeted alternative to existing therapies, with significant advancements in wakefulness enhancement, REM sleep preservation, and cataplexy reduction. The company, in collaboration with Aexon Labs, is also exploring the broader therapeutic applications of AEX-2 and AEX-41 in neurodegenerative and metabolic disorders, with plans to advance these compounds into clinical trials by 2026.

Good afternoon and happy Friday Monk! Are you a buyer at this level or would you watch for a pullback?

Has anyone on this board ever bothered or successfully been able to reach and confirm this information from within either company? If that can’t be done then all of this is a moot point and seems to be insane to continue to think something that cannot be verified and confirmed. Micro penny stocks deals like that are not what you would call confidential in nature. Jmho…GLTYA

Checking in to see how this dog is doing? Looks like this year‘s been a complete dud. I do not get the appeal?

I’m new to this company and then at early stages of DD. Analyst forecasts to be strong, but it sure has had a fall from Grace. I also saw some questioning about potential reverse split. Any insight would be greatly appreciated.

An electric stock race car at that….idiocy!!

Where are we all thinking with recent ODA and RS talk?

Frea*kin rock star report!

Does anyone know "what's up" with this?

Posted from Traders Alley

Ur-Energy (URG)

Strategic Position in the Energy Sector

Ur-Energy, a leading uranium mining company, is strategically positioned to benefit from the growing demand for clean energy. As the world shifts towards sustainable energy sources, uranium, a key component in nuclear energy, is witnessing renewed interest.

Key Growth Drivers

Rising Demand for Nuclear Energy: The global push for carbon-neutral energy sources has led to a resurgence in nuclear energy projects. Ur-Energy, with its rich uranium deposits and efficient extraction processes, is set to benefit from this trend.
Strategic Acquisitions and Partnerships: The company has been proactive in securing strategic acquisitions and partnerships, enhancing its resource base and market reach.
Supportive Regulatory Environment: Governments worldwide are recognizing the role of nuclear energy in achieving climate goals, leading to supportive policies and incentives for uranium producers.
Financial Health and Performance

Ur-Energy has maintained a strong financial position, with a focus on cost control and operational efficiency. The company’s strategic investments in exploration and development have positioned it well to capitalize on the rising demand for uranium.

Future Outlook

As the transition to clean energy accelerates, Ur-Energy is poised for significant growth in 2024. The increasing adoption of nuclear energy, coupled with supportive regulatory frameworks, provides a robust foundation for the company’s future prospects.

Conclusion

In conclusion, Scorpio Tankers, Palantir Technologies, and Ur-Energy each present compelling investment opportunities for 2024. Scorpio Tankers is set to benefit from the recovery in global oil demand and its modern, efficient fleet. Palantir Technologies continues to lead in the AI and big data space, with expanding market applications and strategic partnerships driving its growth. Ur-Energy stands to gain from the rising demand for clean energy and the resurgence of nuclear power as a viable solution for carbon neutrality.

Investors seeking to capitalize on the growth potential in these sectors should consider adding these stocks to their portfolios. Each company, with its unique strengths and strategic positioning, offers the promise of substantial returns in the year ahead. As always, thorough research and due diligence are essential to making informed investment decisions.

🤬🤬 🤬

Yes! Enjoy your weekend!

TO DA MOON....NICE MOVE FOR A FRIDAY!

ASPI
12/16/2024 08:12am

4 Street Research Stories
2 Calendar Events
ASP Isotopes CEO says balance sheet 'has never been stronger'

ASP Isotopes released a letter to shareholders from its Chairman and CEO, Paul Mann, which read in part, "As the year comes towards its end, I wanted to personally write to you to summarize some of the more significant milestones the Company has achieved during 2024 and discuss our future goals for 2025. It has been a busy and successful year: The Company completed the construction of two ASP isotope enrichment facilities, with one awaiting the delivery of feedstock and the second currently in the commissioning phase. The Company completed the construction of the first Quantum Enrichment facility, for Ytterbium-176, approximately 9 months ahead of schedule and under budget. This facility is currently in the commissioning phase and has already successfully produced the first semi-finished material of enriched Ytterbium-176, which is a precursor for the production of Lutetium-177, the active component of Novartis' Pluvicto, a potential blockbuster for the treatment of prostate cancer. The Company signed two contracts with U.S. based customers for the supply of highly enriched Silicon-28 to enable next generation semiconductors for quantum computing, artificial intelligence and large data centers. The Company signed a research contract and a term sheet with TerraPower for the construction of a HALEU production facility. The term sheet anticipates TerraPower providing seed capital for the construction of the facility as well as a long-term supply agreement for the production capacity of the facility. The Company signed an MOU with Nesca to develop an advanced nuclear fuel production facility at Pelindaba, South Africa. ASPI scientists have already had "Shovels in the Ground" at Pelindaba and the construction of the first of two HALEU enrichment test facilities has been completed. The Company raised approximately $84 million in a combination of debt and equity transactions and finished 3Q 2024 with approximately $51 million of cash on balance sheet. The Company's balance sheet has never been stronger. During 2024, the Company hosted over 60 investors and corporate clients to its facilities in South Africa. The company looks forward to hosting another Investor Access Event in January 2025. The construction of two ASP Enrichment Facilities is now complete with one awaiting feedstock, and one in commissioning phase...When we started the Company approximately three years ago we had a headcount of just two individuals. We now have a team of over 130 highly skilled and motivated employees across 3 continents, all of whom are highly motivated to innovate new technologies that can help solve some of today's most pressing challenges such as advanced computing, global warming, and cutting-edge healthcare solutions. It has clearly been a busy year for the Company, and in hitting such an impressive list of milestones, our scientists and engineers have done an amazing job. I'm proud of our entire team, for the work done to date and for the work I expect we will together continue to do going forward. Thank you for your dedication and hard work."

Looking forward to a stellar 2025!

Wonderful, thank you for the update. At doctors appointments today so away from screen.

Wonderful, thank you for the update. At doctors appointments today so away from screen.

Good morning and happy new year lLink! Thank you for the perspective, always appreciate you. I can certainly see that except wer’re now into 2025.

Good morning and happy new year link! Thank you for the perspective, always appreciate you.

See were pushing 7’s this morning

Nice movement up for the start of 2025

Sh%#*% ton of dopey 1 tick flippers!

Nice movement starting 2025.

Seems like tremendous amount of dilution happening. Thoughts?

I feel bad for buyers. Merry Christmas!

Humacyte price target raised to $17 from $15 at Benchmark. Looking forward to 2025. Insider buying and pt upgrades bode well for positive moves going forward.
GLTA
3